中华老年医学杂志
中華老年醫學雜誌
중화노년의학잡지
Chinese Journal of Geriatrics
2013年
10期
1128-1132
,共5页
骨质疏松,绝经后%骨折%系统评价
骨質疏鬆,絕經後%骨摺%繫統評價
골질소송,절경후%골절%계통평개
Osteoporosis,postmenopausal%Fractures,bone%Systems analysis
目的 系统评价阿仑膦酸钠对绝经后妇女骨质疏松性骨折的一级预防和二级预防的作用. 方法 按照Cochrane系统评价的方法,计算机检索美国国立生物医学信息中心Pubmed医学数据库、荷兰医学文摘Embase数据库、Cochrane图书馆临床对照试验数据库(2011年第2期)、中国生物医学文献数据库(CBM)、中文科技期刊全文数据库(CNKI)、万方及维普数据库,并检索所纳入文献的参考文献.收集所有相关随机对照试验,采用Cochrane协作网提供的软件RevMan 5.0进行Meta分析. 结果 共纳入11项随机对照试验进行评价.Meta分析结果显示,就二级预防而言,每天服用10 mg阿仑膦酸钠对减少脊椎、髋、腕部骨折发生率有统计学意义(RR=0.57,95％CI:0.49～0.67)；但就一级预防而言,除减少椎体骨折的发生有统计学意义外(RR=0.55,95％CI:0.38～0.80),未发现减少其他骨折有统计学意义.与阿仑膦酸钠相关的不良反应无增加,敏感性分析结果无改变(RR=0.95,95％CI:0.83～1.09). 结论 阿仑膦酸钠的二级预防能减少绝经后妇女骨质疏松性骨折的发生,仍需对一级预防的疗效进行大样本研究.
目的 繫統評價阿崙膦痠鈉對絕經後婦女骨質疏鬆性骨摺的一級預防和二級預防的作用. 方法 按照Cochrane繫統評價的方法,計算機檢索美國國立生物醫學信息中心Pubmed醫學數據庫、荷蘭醫學文摘Embase數據庫、Cochrane圖書館臨床對照試驗數據庫(2011年第2期)、中國生物醫學文獻數據庫(CBM)、中文科技期刊全文數據庫(CNKI)、萬方及維普數據庫,併檢索所納入文獻的參攷文獻.收集所有相關隨機對照試驗,採用Cochrane協作網提供的軟件RevMan 5.0進行Meta分析. 結果 共納入11項隨機對照試驗進行評價.Meta分析結果顯示,就二級預防而言,每天服用10 mg阿崙膦痠鈉對減少脊椎、髖、腕部骨摺髮生率有統計學意義(RR=0.57,95％CI:0.49～0.67)；但就一級預防而言,除減少椎體骨摺的髮生有統計學意義外(RR=0.55,95％CI:0.38～0.80),未髮現減少其他骨摺有統計學意義.與阿崙膦痠鈉相關的不良反應無增加,敏感性分析結果無改變(RR=0.95,95％CI:0.83～1.09). 結論 阿崙膦痠鈉的二級預防能減少絕經後婦女骨質疏鬆性骨摺的髮生,仍需對一級預防的療效進行大樣本研究.
목적 계통평개아륜련산납대절경후부녀골질소송성골절적일급예방화이급예방적작용. 방법 안조Cochrane계통평개적방법,계산궤검색미국국립생물의학신식중심Pubmed의학수거고、하란의학문적Embase수거고、Cochrane도서관림상대조시험수거고(2011년제2기)、중국생물의학문헌수거고(CBM)、중문과기기간전문수거고(CNKI)、만방급유보수거고,병검색소납입문헌적삼고문헌.수집소유상관수궤대조시험,채용Cochrane협작망제공적연건RevMan 5.0진행Meta분석. 결과 공납입11항수궤대조시험진행평개.Meta분석결과현시,취이급예방이언,매천복용10 mg아륜련산납대감소척추、관、완부골절발생솔유통계학의의(RR=0.57,95％CI:0.49～0.67)；단취일급예방이언,제감소추체골절적발생유통계학의의외(RR=0.55,95％CI:0.38～0.80),미발현감소기타골절유통계학의의.여아륜련산납상관적불량반응무증가,민감성분석결과무개변(RR=0.95,95％CI:0.83～1.09). 결론 아륜련산납적이급예방능감소절경후부녀골질소송성골절적발생,잉수대일급예방적료효진행대양본연구.
Objective To systematically evaluate the efficacy of alendronate on the primary and secondary preventions of osteoporotic fractures in postmenopausal women.Methods Literatures and related references were searched from MEDLINE (from 1966 to April 2011),Embase (from 1966to April 2011),Cochrane Library (the second Issue,2011),CBM disc,CNKI,WANFANG and VIP database by Cochrane systematical evaluation.All related randomized controlled trials were collected,and Meta analysis was performed by RevMan 5.0 soft ware provided by Cochrane collaboration.Results Totally 11 randomized controlled trials were evaluated.Meta-analysis showed that 10 mg oral alendronate daily for secondary prevention could reduce the incidence of spine,hip,wrist and non vertebra fractures (RR 0.57,95％ CI:0.49-0.67),but for the primary prevention,alendronate could not reduce the fracture incidence except for spine fracture (RR=0.55,95％CI:0.38-0.80).Adverse events associated with alendronate were not increased,and the sensitivity analysis results were not changed (RR =0.95,95％ CI:0.83-1.09).Conclusions Alendronate can reduce osteoporotic fractures in postmenopausal women for the secondary prevention,but the effect of alendronate on osteoporotic fractures for the primary prevention needs further study.
